Metastatic Renal Cell Carcinoma Clinical Trial
— SPAZOOfficial title:
Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy, in Patients With Metastatic Renal Cell Carcinoma in Daily Clinical Practice
Verified date | April 2018 |
Source | Spanish Oncology Genito-Urinary Group |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The purpose of this retrospective observational study was to analyze the effect of targeted therapies administered as second-line treatment after failure of pazopanib as well as increase the amount of information available on efficacy and safety of pazopanib as a first-line therapy in practice usual for the clinical treatment of metastatic Renal Carcinoma.
Status | Completed |
Enrollment | 300 |
Est. completion date | April 2015 |
Est. primary completion date | February 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients = 18. - Metastatic renal cell cancer of any histology. - Patients treated with pazopanib for metastatic cell renal cancer outside the context of clinical trials (clinical practice) in Spanish centers from 1 April 2011 until 30 June 2014. shall be included all patients who received pazopanib as first-line treatment in each participating center, whether had experienced treatment failure with pazopanib or were still in first-line treatment. The inclusion of patients who are also allowed received cytokine as first-line treatment followed by pazopanib as well as patients who received sunitinib as first-line treatment and have changed pazopanib for toxicity or intolerance, provided they have not received more a cycle of sunitinib. - Centers that agree to participate must commit to: · Include all patients meeting the inclusion criteria to reduce by possible selection bias. Because it supplies only pazopanib Hospital pharmacy service (not outside hospitals), the identification of patients will be performed at the hospital pharmacy records in each participating center. Exclusion Criteria: - Patients who received pazopanib in clinical trials or treatment second line, with the exceptions noted above. - Patients with the diagnosis and / or treatment of malignancies of importance other than Cell renal cancer. |
Country | Name | City | State |
---|---|---|---|
Spain | Hospital Clínic de Barcelona | Barcelona | |
Spain | Hospital Vall d' Hebron | Barcelona | |
Spain | Hospital San Pedro de Alcántara | Caceres | |
Spain | Hospital G U de Ciudad Real | Ciudad Real | |
Spain | Hospital Reina Sofía | Cordoba | |
Spain | Hospital Universitario de Donostia | Donostia | |
Spain | Hospital San Cecilio | Granada | |
Spain | Hospital General Gran Canaria Dr. Negrín | Las Palmas de Gran Canaria | |
Spain | Hospital de León | León | |
Spain | Hospital San Pedro Logroño | Logroño | |
Spain | Hospital Lucus Augusti | Lugo | |
Spain | Fundacion Jimenez Diaz | Madrid | |
Spain | Hospital Clínico San Carlos | Madrid | |
Spain | Hospital Gregorio Marañon | Madrid | |
Spain | Hospital Quirón | Madrid | |
Spain | Hospital U Puerta de Hierro Majadahonda | Madrid | |
Spain | Hospital Universitario 12 de Octubre | Madrid | |
Spain | Hospital Universitario La Paz | Madrid | |
Spain | Hospital Son Espases | Palma De Mallorca | Mallorca |
Spain | Hospital Provincial de Pontevedra | Pontevedra | |
Spain | Hospital Clínico Universitario Salamanca | Salamanca | |
Spain | Hospital Universitario de Canarias | Santa Cruz de Tenerife | |
Spain | Hospital Marques de Valdecilla | Santander | |
Spain | Hospital Ntra. Sra. De Valme | Sevilla | |
Spain | Hospital Universitario Virgen del Rocío | Sevilla | |
Spain | Hospital Virgen de la Salud | Toledo | |
Spain | Hospital Clínico de Valencia | Valencia | |
Spain | Hospital Gral Universitario Valencia | Valencia | |
Spain | Hospital Universitario Dr. Peset | Valencia | |
Spain | IVO Valencia | Valencia | |
Spain | Hospital Rio Hortega | Valladolid | |
Spain | CHUVI ( Vigo) | Vigo | |
Spain | Hospital Lozano Blesa | Zaragoza | |
Spain | Hospital Miguel Servet | Zaragoza |
Lead Sponsor | Collaborator |
---|---|
Spanish Oncology Genito-Urinary Group |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Describe the efficacy in terms of response | Describe the efficacy in terms of response of second-line targeted therapies administered in patients with metastatic clear cell carcinoma treated pazopanib as a first-line therapy in routine clinical practice (unselected population). | 3 years | |
Primary | Describe the efficacy in terms of progression-free survival (PFS) | Describe the efficacy in terms of progression-free survival (PFS) of second-line targeted therapies administered in patients with metastatic clear cell carcinoma treated pazopanib as a first-line therapy in routine clinical practice (unselected population). | 3 years | |
Primary | Describe the efficacy in terms of overall survival (OS) | Describe the efficacy in terms of overall survival (PFS) of second-line targeted therapies administered in patients with metastatic clear cell carcinoma treated pazopanib as a first-line therapy in routine clinical practice (unselected population). | 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00930033 -
Clinical Trial to Assess the Importance of Nephrectomy
|
Phase 3 | |
Recruiting |
NCT05863351 -
Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study
|
Phase 3 | |
Not yet recruiting |
NCT06284564 -
A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)
|
Phase 2 | |
Completed |
NCT00414765 -
Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma
|
Phase 4 | |
Active, not recruiting |
NCT03149822 -
Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT03647878 -
Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.
|
||
Completed |
NCT01517243 -
Phase II Study of Alternating Sunitinib and Temsirolimus
|
Phase 2 | |
Withdrawn |
NCT03927248 -
PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT02122003 -
Second Line Sorafenib After Pazopanib in Patients With RCC
|
Phase 2 | |
Completed |
NCT01182142 -
Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients
|
Phase 2 | |
Completed |
NCT00630409 -
Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma
|
Phase 2 | |
Recruiting |
NCT04140526 -
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
|
Phase 1/Phase 2 | |
Completed |
NCT04076787 -
Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib
|
||
Active, not recruiting |
NCT04467021 -
Cancer and Blood Pressure Management, CARISMA Study
|
N/A | |
Recruiting |
NCT05119335 -
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
|
Phase 1/Phase 2 | |
Completed |
NCT01731158 -
Sequential Therapy in Metastatic Renal Cell Carinoma
|
Phase 2 | |
Terminated |
NCT02071641 -
Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma
|
Phase 2 | |
Terminated |
NCT01342627 -
Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT01274273 -
Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer
|
Phase 2 | |
Completed |
NCT00848640 -
Study of Sorafenib in Patients With Advanced Renal Cell Carcinoma
|
Phase 2 |